NewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Rating of “Buy” from Analysts

NewAmsterdam Pharma (NASDAQ:NAMSGet Free Report) has received a consensus rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $43.33.

Several analysts recently weighed in on NAMS shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Scotiabank boosted their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Thursday, February 27th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a report on Monday, March 3rd. Needham & Company LLC cut their price target on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th.

Get Our Latest Report on NewAmsterdam Pharma

Insiders Place Their Bets

In related news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. The trade was a 90.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James N. Topper acquired 4,005 shares of the company’s stock in a transaction on Tuesday, March 4th. The stock was purchased at an average cost of $21.02 per share, for a total transaction of $84,185.10. Following the completion of the transaction, the director now owns 3,012,434 shares in the company, valued at approximately $63,321,362.68. The trade was a 0.13 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 388,916 shares of company stock worth $9,231,268 in the last quarter. 19.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after buying an additional 1,399 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth about $50,000. National Bank of Canada FI purchased a new stake in NewAmsterdam Pharma during the fourth quarter worth approximately $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in NewAmsterdam Pharma in the fourth quarter valued at approximately $80,000. Finally, Legal & General Group Plc increased its stake in NewAmsterdam Pharma by 24.8% in the fourth quarter. Legal & General Group Plc now owns 22,946 shares of the company’s stock valued at $590,000 after purchasing an additional 4,556 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Trading Down 0.1 %

Shares of NASDAQ:NAMS opened at $23.34 on Tuesday. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of -8.98 and a beta of -0.04. NewAmsterdam Pharma has a 12-month low of $15.19 and a 12-month high of $27.29. The business has a 50-day moving average price of $21.90 and a 200 day moving average price of $20.83.

NewAmsterdam Pharma (NASDAQ:NAMSGet Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. As a group, equities research analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

About NewAmsterdam Pharma

(Get Free Report

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Read More

Analyst Recommendations for NewAmsterdam Pharma (NASDAQ:NAMS)

Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.